AR121589A1 - Combinación que comprende alpelisib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico - Google Patents
Combinación que comprende alpelisib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílicoInfo
- Publication number
- AR121589A1 AR121589A1 ARP210100523A ARP210100523A AR121589A1 AR 121589 A1 AR121589 A1 AR 121589A1 AR P210100523 A ARP210100523 A AR P210100523A AR P210100523 A ARP210100523 A AR P210100523A AR 121589 A1 AR121589 A1 AR 121589A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- alpelisib
- oxyphenyl
- fluoropropyl
- pyrrolidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305190 | 2020-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121589A1 true AR121589A1 (es) | 2022-06-22 |
Family
ID=69784379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100523A AR121589A1 (es) | 2020-02-27 | 2021-02-26 | Combinación que comprende alpelisib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12427142B2 (enExample) |
| EP (1) | EP4110326B1 (enExample) |
| JP (1) | JP2023516951A (enExample) |
| KR (1) | KR20220146473A (enExample) |
| CN (1) | CN115209893B (enExample) |
| AR (1) | AR121589A1 (enExample) |
| AU (1) | AU2021227007A1 (enExample) |
| BR (1) | BR112022015972A2 (enExample) |
| CA (1) | CA3168936A1 (enExample) |
| IL (1) | IL295807A (enExample) |
| MX (1) | MX2022010539A (enExample) |
| TW (1) | TW202146007A (enExample) |
| WO (1) | WO2021170793A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992015579A1 (en) | 1991-03-08 | 1992-09-17 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
| DE19833786A1 (de) | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| ES2236056T3 (es) | 2001-01-24 | 2005-07-16 | Chiesi Farmaceutici S.P.A. | Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos. |
| EP1417169A2 (en) | 2001-08-11 | 2004-05-12 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
| ATE481397T1 (de) | 2002-04-24 | 2010-10-15 | Merck Sharp & Dohme | Modulatoren des östrogenrezeptors |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| ES2573845T3 (es) | 2004-06-25 | 2016-06-10 | Janssen Pharmaceutica Nv | Antagonistas de CCR2 de sales cuaternarias |
| CA2611712C (en) | 2005-06-14 | 2014-05-13 | Baylor University | Combretastatin analogs with tubulin binding activity |
| US8127618B1 (en) | 2007-05-18 | 2012-03-06 | Pacesetter, Inc. | Implantable micro-electromechanical system sensor |
| EP2048126A1 (de) | 2007-10-11 | 2009-04-15 | Bayer Schering Pharma AG | Benzocycloheptanderivate als selektiv wirksame Estrogene |
| WO2009101634A2 (en) | 2008-02-13 | 2009-08-20 | Lupin Limited | A novel process for the preparation of eszopiclone |
| DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| US20120130129A1 (en) | 2010-11-16 | 2012-05-24 | Baylor University | Efficient Method for Preparing Functionalized Benzosuberenes |
| CA2819299A1 (en) | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| CN102584687A (zh) | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
| KR20150039705A (ko) | 2011-12-30 | 2015-04-13 | 켄타우루스 바이오파마 컴퍼니 리미티드 | 신규 아릴알켄 유도체 및 이의 선택성 에스트로겐 수용체 조절제에 있어서의 응용 |
| EP4772247A2 (en) | 2013-08-14 | 2026-07-08 | Novartis AG | Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer |
| WO2015028409A1 (de) | 2013-08-27 | 2015-03-05 | Bayer Pharma Aktiengesellschaft | 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| MX2016007282A (es) | 2013-12-06 | 2016-09-07 | Hoffmann La Roche | Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico. |
| EP3200772B1 (en) | 2014-10-03 | 2022-08-03 | Novartis AG | Pharmaceutical compositions comprising alpelisib |
| WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| TWI784255B (zh) | 2014-12-18 | 2022-11-21 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| MX384605B (es) | 2015-04-29 | 2025-03-14 | Radius Pharmaceuticals Inc | Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. |
| US10144728B2 (en) * | 2015-10-06 | 2018-12-04 | Dow Agrosciences Llc | Alkylation of picolinamides with substituted chloroacylals utilizing a crown ether catalyst |
| CN106924210A (zh) | 2015-12-29 | 2017-07-07 | 北京新领先医药科技发展有限公司 | 一种含有帕布昔利布的胶囊剂及其制备方法 |
| SG11201806829TA (en) | 2016-02-15 | 2018-09-27 | Sanofi Sa | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators |
| EP3541809B1 (en) | 2016-11-17 | 2025-06-25 | Sanofi | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| WO2019106604A1 (en) * | 2017-12-01 | 2019-06-06 | Novartis Ag | Pharmaceutical combination comprising lsz102 and alpelisib |
| CN109896991B (zh) | 2017-12-08 | 2020-11-20 | 苏州远智医药科技有限公司 | 一种δ阿片受体拮抗剂及其用途和药物组合物 |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| EP3880202A2 (en) | 2018-11-16 | 2021-09-22 | ArQule, Inc. | Pharmaceutical combination for treatment of cancer |
| WO2020112765A1 (en) | 2018-11-30 | 2020-06-04 | Radius Pharmaceuticals, Inc. | Elacestrant in combination with abemaciclib in women with breast cancer |
| SG11202111979SA (en) | 2019-05-09 | 2021-11-29 | Sanofi Sa | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| EP4069225A4 (en) * | 2019-12-20 | 2023-12-27 | Recurium IP Holdings, LLC | COMBINATIONS |
| MX2022010425A (es) * | 2020-03-06 | 2022-09-07 | Olema Pharmaceuticals Inc | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| WO2022106711A1 (en) | 2020-11-23 | 2022-05-27 | Sanofi | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| TW202304424A (zh) | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含依維莫司和安森司群的組合 |
| TW202304425A (zh) | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合 |
-
2021
- 2021-02-25 TW TW110106633A patent/TW202146007A/zh unknown
- 2021-02-26 CA CA3168936A patent/CA3168936A1/en active Pending
- 2021-02-26 JP JP2022551616A patent/JP2023516951A/ja not_active Ceased
- 2021-02-26 US US17/802,223 patent/US12427142B2/en active Active
- 2021-02-26 EP EP21707690.0A patent/EP4110326B1/en active Active
- 2021-02-26 BR BR112022015972A patent/BR112022015972A2/pt not_active Application Discontinuation
- 2021-02-26 WO PCT/EP2021/054815 patent/WO2021170793A1/en not_active Ceased
- 2021-02-26 AU AU2021227007A patent/AU2021227007A1/en not_active Abandoned
- 2021-02-26 AR ARP210100523A patent/AR121589A1/es not_active Application Discontinuation
- 2021-02-26 IL IL295807A patent/IL295807A/en unknown
- 2021-02-26 MX MX2022010539A patent/MX2022010539A/es unknown
- 2021-02-26 CN CN202180017056.6A patent/CN115209893B/zh active Active
- 2021-02-26 KR KR1020227029446A patent/KR20220146473A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4110326A1 (en) | 2023-01-04 |
| JP2023516951A (ja) | 2023-04-21 |
| IL295807A (en) | 2022-10-01 |
| CA3168936A1 (en) | 2021-09-02 |
| TW202146007A (zh) | 2021-12-16 |
| BR112022015972A2 (pt) | 2022-10-11 |
| US12427142B2 (en) | 2025-09-30 |
| WO2021170793A1 (en) | 2021-09-02 |
| EP4110326B1 (en) | 2024-01-31 |
| KR20220146473A (ko) | 2022-11-01 |
| CN115209893A (zh) | 2022-10-18 |
| CN115209893B (zh) | 2024-08-30 |
| EP4110326C0 (en) | 2024-01-31 |
| US20230089371A1 (en) | 2023-03-23 |
| MX2022010539A (es) | 2022-09-21 |
| AU2021227007A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| PY2240956A (es) | Nuevos Compuestos bicíclicos y sus usos | |
| BR112022015972A2 (pt) | Combinação compreendendo alpelisibe e ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-idro-7h-benzo[7]anuleno-2-carboxílico | |
| AR125331A1 (es) | Combinación que comprende ribociclib y amcenestrant | |
| PY2121402A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| CO2022016153A2 (es) | Inhibidores de il4i1 y métodos de uso | |
| MX2025014865A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| CL2024000738A1 (es) | Profármaco de derivados de pirrolidona como activador de glucocinasa | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| JP2023516951A5 (enExample) | ||
| MX2025008259A (es) | Inhibidores de prmt5-mta | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| AR128106A1 (es) | Tetrahidrobenzoazepinonas y análogos relacionados para la inhibición de yap / taz-tead | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| AR127966A1 (es) | Formulaciones tópicas de inhibidores de pi3k-delta | |
| AR074737A1 (es) | Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il) metanona-n-carboxamida y composicion farmaceutica que los contiene | |
| BR112022016124A2 (pt) | Composto de di-hidronaftiridinona, e método de preparação para este e uso médico deste | |
| AR131503A1 (es) | Antagonistas de hpk1 espirocíclicos y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |